INTELLIA THERAPEUTICS H-1B Visa Sponsorship & Salary Data

The median H-1B salary at INTELLIA THERAPEUTICS is $126,400, based on 71 certified filings from FY 2020 to FY 2026. This is 5% higher than the national H-1B median salary of $120,000. Compensation at INTELLIA THERAPEUTICS reflects their market positioning, with entry-level roles starting around $112,000 and senior positions reaching $180,000 or higher. These figures represent base salaries in LCA filings and may not include bonuses, equity grants, or other compensation common at large employers.

Salaries at INTELLIA THERAPEUTICS range from $88,500 at the 10th percentile to $180,000 at the 90th percentile, showing a $91,500 spread across experience levels and roles. The 25th percentile is $112,000 and the 75th percentile is $143,600.

Yes, INTELLIA THERAPEUTICS actively sponsors H-1B visas in FY 2026. In the most recent fiscal year (FY 2026), INTELLIA THERAPEUTICS filed 1 H-1B labor condition applications with 1 certified and 0 denied, at a median salary of $177,900. Across FY 2020–2026, they have filed 71 total H-1B applications with 71 certified and a 0% lifetime denial rate, demonstrating ongoing commitment to hiring international talent. INTELLIA THERAPEUTICS sponsors positions across multiple job categories and locations, making them a viable option for professionals seeking H-1B visa sponsorship.

In the most recent fiscal year (FY 2026), INTELLIA THERAPEUTICS filed 1 H-1B applications, with 1 certified and 0 denied. Over 7 years of data, INTELLIA THERAPEUTICS has consistently demonstrated commitment to H-1B sponsorship.

Note: These are Labor Condition Applications (LCAs) filed with the Department of Labor, which is a prerequisite for H-1B petitions. The actual number of H-1B petitions filed with USCIS may differ.

INTELLIA THERAPEUTICS's LCA (Labor Condition Application) denial rate is 0%, with 0 out of 71 applications denied across all years. This translates to a 100.0% certification rate, which indicates how successfully the company prepares and files H-1B applications. A lower denial rate suggests better compliance with Department of Labor requirements, proper wage documentation, and accurate job classification. Prospective H-1B applicants should consider this approval rate alongside other factors like salary, job role, and location when evaluating INTELLIA THERAPEUTICS as a potential H-1B sponsor.

This is an excellent approval rate, indicating INTELLIA THERAPEUTICS has strong H-1B sponsorship practices and typically meets DOL requirements. Applicants can feel confident in the company's H-1B track record.

INTELLIA THERAPEUTICS sponsors H-1B visas for various specialty occupation positions requiring at least a bachelor's degree. Based on 71 certified filings, the most commonly sponsored job titles reflect the company's primary business functions and talent needs. These positions typically require specialized knowledge in fields like technology, engineering, finance, or scientific research. Understanding which roles INTELLIA THERAPEUTICS most frequently sponsors can help job seekers target their applications effectively.

Most common H-1B job titles at INTELLIA THERAPEUTICS:

The most frequently sponsored role is Senior Research Scientist with 18 filings at a median salary of $127,900. This is followed by Associate Research Scientist (14 filings) and Research Scientist.

INTELLIA THERAPEUTICS's H-1B positions are distributed across multiple U.S. locations, with concentration in major metropolitan areas and tech hubs. Geographic distribution often reflects company office locations, client sites, and regional market demands. Location significantly impacts H-1B salary due to varying cost of living and local wage requirements. Understanding where INTELLIA THERAPEUTICS sponsors H-1B workers can help candidates target specific offices and negotiate appropriate compensation for each market.

Top INTELLIA THERAPEUTICS H-1B locations:

The largest H-1B hub for INTELLIA THERAPEUTICS is Cambridge, MA with 71 filings at a median salary of $126,400.

INTELLIA THERAPEUTICS's median H-1B salary has increased by +101% from FY 2020 ($88,500) to FY 2026 ($177,900). Tracking salary trends over time reveals how INTELLIA THERAPEUTICS adjusts compensation to remain competitive in the H-1B labor market. Salary growth typically reflects inflation adjustments, increased demand for specialized skills, and evolving prevailing wage requirements. These historical trends can help applicants understand future salary expectations and negotiate appropriately when considering H-1B opportunities at INTELLIA THERAPEUTICS.

Year-by-year breakdown:

• FY 2022: $120,000 (3 certified)
• FY 2023: $126,900 (3 certified)
• FY 2024: $127,900 (37 certified)
• FY 2025: $142,400 (13 certified)
• FY 2026: $177,900 (1 certified)

This 101% growth reflects strong compensation adjustments at INTELLIA THERAPEUTICS, keeping pace with market demands for H-1B talent.

INTELLIA THERAPEUTICS primarily files H-1B applications at Wage Level IV, accounting for 41% of their filings. DOL wage levels range from Level I (entry-level, 17th percentile of local wages) to Level IV (expert, 67th percentile). Wage level determines both salary requirements and, under recent H-1B rules, lottery selection priority. Higher wage levels receive preference in the H-1B lottery, making INTELLIA THERAPEUTICS's wage level distribution an important factor for prospective applicants assessing their chances of H-1B selection.

With 89% of positions at Level II or higher, INTELLIA THERAPEUTICS typically offers competitive wages above entry-level. Higher wage levels receive priority in the H-1B lottery.

INTELLIA THERAPEUTICS's median H-1B salary of $126,400 is 5% higher than the national H-1B median of $120,000 across all employers and industries. This comparison provides context for evaluating INTELLIA THERAPEUTICS's competitiveness in attracting H-1B talent. Keep in mind that industry, location, and job function significantly impact salary levels. Tech companies and financial institutions typically offer higher H-1B salaries than other sectors, while salaries in major metros like San Francisco and New York exceed those in smaller markets. Compare INTELLIA THERAPEUTICS's offerings with similar companies in your field for a more accurate assessment.

INTELLIA THERAPEUTICS offers above-average H-1B compensation. Combined with their 71 certified filings and 0% denial rate, they demonstrate solid H-1B sponsorship practices.

Recent H-1B rule changes have increased filing fees and introduced wage-level prioritization in the lottery. INTELLIA THERAPEUTICS's higher proportion of Level III-IV positions (73%) may benefit from wage-based lottery prioritization.

With 71 certified filings, INTELLIA THERAPEUTICS invests significantly in H-1B sponsorship. The company's 0% denial rate suggests strong compliance with H-1B requirements and documentation standards.

Note: H-1B regulations are subject to change. Fees shown are estimates based on 2024 USCIS fee schedules. Actual costs may vary based on company size, premium processing, and future rule changes.